SCHEMBL34475240

SCHEMBL34475240

O=C(O)c1ccccc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.78
▸ KMT2A Q03164 5/20 0.78
▸ LMNA P02545 1/20 0.78
▸ ACLY P53396 1/20 0.74
▸ SLC25A1 P53007 1/20 0.73
▸ KDM4E B2RXH2 2/20 0.68
▸ POLB P06746 1/20 0.68
▸ CCR2 P41597 5/20 0.65
▸ CYP1A2 P05177 2/20 0.65
▸ CYP3A4 P08684 2/20 0.65
▸ CYP2D6 P10635 2/20 0.65
▸ CYP2C9 P11712 2/20 0.65
▸ CYP2C19 P33261 2/20 0.65
▸ CCR4 P51679 2/20 0.65
▸ CCR5 P51681 2/20 0.65
▸ KCNH2 Q12809 1/20 0.65
▸ ALDH1A1 P00352 3/20 0.62
▸ HSD17B10 Q99714 1/20 0.62
▸ PTGES2 Q9H7Z7 1/20 0.60
▸ GAA P10253 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27770307 0.91 MEN1 (0.78) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL3088122 0.88 KMT2A (0.62) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL10695037 0.88 MEN1 (0.73) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL21999967 0.85 ACLY (1.00) ACLY
SCHEMBL643467 0.85 LMNA (0.66) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL492000 0.84 ACLY (0.72) ACLYCCR2CYP1A2CYP3A4CYP2D6
SCHEMBL3089865 0.84 ACLY (0.73) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL30000258 0.84 SLC25A1 (1.00) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL29918322 0.84 SLC25A1 (1.00) MEN1KMT2ALMNAACLYSLC25A1
SCHEMBL30777865 0.84 SLC25A1 (1.00) MEN1KMT2ALMNAACLYSLC25A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026088050-A1 SMALL MOLECULE INHIBITOR OF FOXA1 AND FOXA2 FOR THE TREATMENT OF FOXA1/FOXA2-DEPENDENT CANCERS OR OTHER DISEASES FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR) (CH) 2026-04-30 — — WO disclosed
Send feedback